School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China Institute of Molecular Physiology, Shenzhen Bay Laboratory, Shenzhen 518132, China ...

Previously presented at ESMO 2023, 177 Lu-PSMA-617 prolonged radiographic progression-free survival versus change of androgen receptor pathway inhibitor in taxane-naïve patients with mCRPC in PSMAfore ...

Antibody therapies are a type of biologic. They are typically monoclonal antibodies selected to bind to a particular protein (often a cell-surface protein), and produced using recombinant DNA ...

Amino acid additions are usually favored, predominantly by seniors, due to their beneficial impacts on muscle development and mending, enhancement of thinking abilities, and promotion of holistic ...

177Lu-PNT6555 is under clinical development by Eli Lilly and Co and currently in Phase I for Esophageal Squamous Cell Carcinoma (ESCC). According to GlobalData, Phase I drugs for Esophageal Squamous ...

Andrey Cherkasov - stock.adobe.com For those who got deep into the holiday spirits, there’s an amino acid that may be able to alleviate your hangover. Drinking plenty of water, taking a pain ...

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

(Hint: It’s a lot.) A biggie as of late? Amino acids, which are the building blocks of protein. The 11 amino acids our bodies synthesize are called “nonessential,” but we need nine others (k ...

The phase 1 first-in-human study is designed to assess the safety, tolerability & preliminary clinical activity of 177Lu-RAD202 in individuals with HER2-positive metastatic solid tumours. The ...

Dec 23 (Reuters) - The U.S. Food and Drug Administration has revoked the emergency use authorization for four COVID-19 antibody-based drugs, including those from Eli Lilly (LLY.N), opens new tab ...

SYDNEY, Australia I December 20, 2024 I Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology ...

Phase 1 therapeutic clinical study of 177Lu-labelled RAD 202 for the treatment of HER2-expressing solid tumors. The open-label Phase 1 trial, entitled ‘HEAT’ (HER2 Antibody Therapy with Lutetium-177), ...